Trubion Pharmaceuticals, Inc. (Nasdaq:TRBN) shares are falling after the firm announced after Thursday’s close that its partner, Wyeth Pharmaceuticals, halted the study of Trubion’s early-stage study of its non-Hodgkin's lymphoma treatment. Trubion was four months into the study of its therapy TRU-015. In stopping the study, Trubion said in a statement that Wyeth “has determined not to pursue such therapies for oncology indications.” In afternoon trading, TRBN shares are down 11.29%, or $1.39, at $10.92.

For detailed price information and recent news stories about Trubion Pharmaceuticals, click TRBN.